In line with this, a novel breast cancer signature consisting of CRGs such as PGK1, SLC52A2, and RAD23B has shown potential for prognosis prediction, with RAD23B emerging as a promising target linked to disease progression and drug resistance (Song et al., 2022). This evidence concerns the gene RAD23B and breast cancer.